The cardiovascular and cardiac actions of ecstasy and its metabolites

Current Pharmaceutical Biotechnology

Volumn 11, Issue 5, 2010, Pages 470-475

  Shenouda, S K ^a,c   Varner, K J ^b   Carvalho, F ^a  

^a LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PORTO   (Portugal)

^c ELI LILLY AND COMPANY   (United States)

Author keywords

3,4 methylenedioxymethamphetamine; Blood pressure; Cardiac toxicity; Heart; MDMA; Oxidative stress

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; 4 AMINOBUTYRIC ACID RECEPTOR STIMULATING AGENT; ALPHA 2 ADRENERGIC RECEPTOR; COCAINE; DOBUTAMINE; DRUG METABOLITE; GLUTATHIONE; HISTAMINE H1 RECEPTOR; METHAMPHETAMINE; MUSCARINIC M1 RECEPTOR; MUSCIMOL; REACTIVE OXYGEN METABOLITE; SEROTONIN 2A RECEPTOR;

ARTERIAL PRESSURE; ARTICLE; AUTOPSY; BEHAVIOR; BLOOD PRESSURE; BRAIN; CARDIOMYOPATHY; CARDIOTOXICITY; CARDIOVASCULAR EFFECT; DOSE RESPONSE; DRUG ABUSE; DRUG EFFECT; ECHOCARDIOGRAPHY; HEART; HEART ARRHYTHMIA; HEART FUNCTION; HEART INFARCTION; HEART MUSCLE CONTRACTILITY; HEART RATE; HEART VENTRICLE HYPERTROPHY; HUMAN; NONHUMAN; OXIDATIVE STRESS; SUDDEN DEATH;

ANIMALS; HALLUCINOGENS; HEART; HEART DISEASES; HUMANS; MODELS, CARDIOVASCULAR; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; REACTIVE OXYGEN SPECIES;

ANIMALIA;

EID: 77956574337     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/138920110791591526     Document Type: Article

References (70)

1. Nichols, D.E. Differences between the mechanism of action ofMDMA, MBDB, and the classic hallucinogens. Identification of anew therapeutic class: entactogens. J. Psychoactive. Drugs, 1986,18(4), 305-313
2. Cohen, R.S. The Love Drug. Marching to the Beat of Ecstasy; Haworth Medical Press: Binghamton, NY, 1998, p. 166
3. Green, A.R.; Cross, A.J.; Goodwin, G.M. Review of the pharma-cology and clinical pharmacology of 3,4-methylenedioxy-methamphetamine (MDMA or Ecstasy). Psychopharmacology,1995, 119(3), 247-260
4. Steele, T.D.; McCann, U.D.; Ricaurte, G.A. 3,4-Methyl-enedioxy-methamphetamine (MDMA, Ecstasy): pharmacology and toxi-cology in animals and humans. Addiction, 1994, 89(5), 539-551.
5. Morgan, M.J. Ecstasy (MDMA): a review of its possible persistentpsychological effects. Psychopharmacology, 2000, 152(3), 230-248
6. Zakzanis, K.K.; Young, D.A. Memory impairment in abstinentMDMA (Ecstasy) users: a longitudinal investigation. Neurology,2001, 56(7), 966-969
7. Thomasius, R.; Zapletalova, P.; Petersen, K.; Buchert, R.; Andre-sen, B.; Wartberg, L.; Nebeling, B.; Schmoldt, A. Mood, cognitionand serotonin transporter availability in current and former ecstasy(MDMA) users: the longitudinal perspective. J. Psychopharmacol.,2006, 20(2), 211-225
8. Gough, B.; Ali, S.F.; Slikker, W. Jr.; Holson, R.R. Acute effects of3,4-methylenedioxymethamphetamine (MDMA) on monoaminesin rat caudate. Pharmacol. Biochem. Behav., 1991, 39(3), 619-623.
9. Gudelsky, G.A.; Nash, J.F. Carrier-mediated release of serotoninby 3,4-methylenedioxymethamphetamine: implications for sero-tonin-dopamine interactions. J. Neurochem., 1996, 66(1), 243-249.
10. Mechan, A.O.; Esteban, B.; O'Shea, E.; Elliott, J.M.; Colado, M.I.; Green, A.R. The pharmacology of the acute hyperthermic responsethat follows administration of 3,4-methylenedioxy-methamp-hetamine (MDMA, 'ecstasy') to rats. Br. J. Pharmacol., 2002,135(1), 170-180
11. Nash, J.F.; Brodkin, J. Microdialysis studies on 3,4-methyl-enedioxymethamphetamine-induced dopamine release: effect ofdopamine uptake inhibitors. J. Pharmacol. Exp. Ther., 1991,259(2), 820-825
12. Johnson, M.P.; Hoffman, A.J.; Nichols, D.E. Effects of the enanti-omers of MDA, MDMA and related analogues on [3H]serotoninand [3H]dopamine release from superfused rat brain slices. Eur. J.Pharmacol., 1986, 132(2-3), 269-276
13. Fitzgerald, J.L.; Reid, J.J. Effects of methylenedioxymetham-phetamine on the release of monoamines from rat brain slices. Eur.J. Pharmacol., 1990, 191(2), 217-220
14. Bengel, D.; Murphy, D.L.; Andrews, A.M.; Wichems, C.H.; Felt-ner, D.; Heils, A.; Mossner, R.; Westphal, H.; Lesch, K.P. Alteredbrain serotonin homeostasis and locomotor insensitivity to 3, 4-methylenedioxymethamphetamine (Ecstasy) in serotonin trans-porter-deficient mice. Mol. Pharmacol., 1998, 53(4), 649-655.
15. Fitzgerald, J.L.; Reid, J.J. Sympathomimetic actions of methyle-nedioxymethamphetamine in rat and rabbit isolated cardiovasculartissues. J. Pharm. Pharmacol., 1994, 46(10), 826-832
16. Leonardi, E.T.; Azmitia, E.C. MDMA (ecstasy) inhibition of MAOtype A and type B: comparisons with fenfluramine and fluoxetine(Prozac). Neuropsychopharmacology, 1994, 10(4), 231-238.
17. Schmidt, C.J.; Taylor, V.L. Direct central effects of acute methyle-nedioxymethamphetamine on serotonergic neurons. Eur. J. Phar-macol., 1988, 156(1), 121-131
18. Che, S.; Johnson, M.; Hanson, G.R.; Gibb, J.W. Body temperatureeffect on methylenedioxymethamphetamine-induced acute decreasein tryptophan hydroxylase activity. Eur. J. Pharmacol., 1995,293(4), 447-453
19. Stone, D.M.; Johnson, M.; Hanson, G.R.; Gibb, J.W. Role of en-dogenous dopamine in the central serotonergic deficits induced by3,4-methylenedioxymethamphetamine. J. Pharmacol. Exp. Ther.,1988, 247(1), 79-87
20. Stone, D.M.; Hanson, G.R.; Gibb, J.W. Differences in the centralserotonergic effects of methylenedioxymethamphetamine (MDMA)in mice and rats. Neuropharmacology, 1987, 26(11), 1657-1661.
21. Stone, D.M.; Merchant, K.M.; Hanson, G.R.; Gibb, J.W. Immediate and long-term effects of 3,4-methylenedioxymethamphetamineon serotonin pathways in brain of rat. Neuropharmacology, 1987,26(12), 1677-1683
22. McDaid, J.; Docherty, J.R. Vascular actions of MDMA involvealpha1 and alpha2-adrenoceptors in the anaesthetized rat. Br. J.Pharmacol., 2001, 133(3), 429-437
23. Newton, R.A.; Phipps, S.L.; Flanigan, T.P.; Newberry, N.R.; Carey, J.E.; Kumar, C.; McDonald, B.; Chen, C.; Elliott, J.M. Characterisation of human 5-hydroxytryptamine2A and 5-hydroxytryptamine2C receptors expressed in the human neuroblastoma cell line SH-SY5Y: comparative stimulation by hallucino-genic drugs. J. Neurochem., 1996, 67(6), 2521-2531
24. Capela, J.P.; Ruscher, K.; Lautenschlager, M.; Freyer, D.; Dirnagl, U.; Gaio, A.R.; Bastos, M.L.; Meisel, A.; Carvalho, F. Ecstasy-induced cell death in cortical neuronal cultures is serotonin 2A-receptor-dependent and potentiated under hyperthermia. Neurosci-ence, 2006, 139(3), 1069-1081
25. Green, A.R.; Mechan, A.O.; Elliott, J.M.; O'Shea, E.; Colado, M.I. The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy). Pharma-col. Rev., 2003, 55(3), 463-508
26. Dowling, G.P.; McDonough, E.T., 3rd; Bost, R.O. 'Eve' and 'Ec-stasy'. A report of five deaths associated with the use of MDEA andMDMA. J. Am. Med. Assoc., 1987, 257(12), 1615-1617.
27. Mas, M.; Farre, M.; de la Torre, R.; Roset, P.N.; Ortuno, J.; Segura, J.; Cami, J. Cardiovascular and neuroendocrine effects and phar-macokinetics of 3, 4-methylenedioxymethamphetamine in humans.J. Pharmacol. Exp. Ther., 1999, 290(1), 136-145
28. Vollenweider, F.X.; Gamma, A.; Liechti, M.; Huber, T. Psycho-logical and cardiovascular effects and short-term sequelae ofMDMA (ecstasy) in MDMA-naive healthy volunteers. Neuro-psychopharmacology, 1998, 19(4), 241-251
29. Lester, S.J.; Baggott, M.; Welm, S.; Schiller, N.B.; Jones, R.T.; Foster, E.; Mendelson, J. Cardiovascular effects of 3,4-methylenedioxymethamphetamine. A double-blind, placebo-controlled trial. Ann. Intern. Med., 2000, 133(12), 969-973.
30. Dumont, G.; Schoemaker, R.; Touw, D.; Sweep, F.; Buitelaar, J.; van Gerven, J.; Verkes, R. Acute psychomotor effects of MDMAand ethanol (co-) administration over time in healthy volunteers. J.Psychopharmacol., 2010, 24(2), 155-164
31. Liechti, M.E.; Vollenweider, F.X. Acute psychological and physio-logical effects of MDMA (Ecstasy) after haloperidol pretreatmentin healthy humans. Eur. Neuropsychopharmacol., 2000, 10(4),289-295
32. Farre, M.; Abanades, S.; Roset, P.N.; Peiro, A.M.; Torrens, M.; O'Mathuna, B.; Segura, M.; de la Torre, R. Pharmacological inter-action between 3,4-methylenedioxymethamphetamine (ecstasy)and paroxetine: pharmacological effects and pharmacokinetics. J.Pharmacol. Exp. Ther., 2007, 323(3), 954-962
33. Tancer, M.; Johanson, C.E. The effects of fluoxetine on the subjec-tive and physiological effects of 3,4-methylenedioxy-methamphetamine (MDMA) in humans. Psychopharmacology,2007, 189(4), 565-573
34. O'Cain, P.A.; Hletko, S.B.; Ogden, B.A.; Varner, K.J. Cardiovascu-lar and sympathetic responses and reflex changes elicited byMDMA. Physiol. Behav., 2000, 70(1-2), 141-148
35. Pedersen, N.P.; Blessing, W.W. Cutaneous vasoconstriction con-tributes to hyperthermia induced by 3,4-methylenedioxy-methamphetamine (ecstasy) in conscious rabbits. J. Neurosci.,2001, 21(21), 8648-8654
36. Badon, L.A.; Hicks, A.; Lord, K.; Ogden, B.A.; Meleg-Smith, S.; Varner, K.J. Changes in cardiovascular responsiveness and car-diotoxicity elicited during binge administration of Ecstasy. J.Pharmacol. Exp. Ther., 2002, 302(3), 898-907
37. Rusyniak, D.E.; Zaretskaia, M.V.; Zaretsky, D.V.; DiMicco, J.A. Microinjection of muscimol into the dorsomedial hypothalamussuppresses MDMA-evoked sympathetic and behavioral responses. Brain Res., 2008, 1226, 116-123
38. Bexis, S.; Docherty, J.R. Effects of MDMA, MDA and MDEA onblood pressure, heart rate, locomotor activity and body temperaturein the rat involve alpha-adrenoceptors. Br. J. Pharmacol., 2006,147(8), 926-934
39. Vandeputte, C.; Docherty, J.R. Vascular actions of 3,4-methylenedi-oxymethamphetamine in alpha(2A/D)-adrenoceptorknockout mice. Eur. J. Pharmacol., 2002, 457(1), 45-49
40. McNamara, R.; Maginn, M.; Harkin, A. Caffeine induces a pro-found and persistent tachycardia in response to MDMA (Ecstasy)administration. Eur. J. Pharmacol., 2007, 555(2-3), 194-198.
41. McCann, U.D.; Ridenour, A.; Shaham, Y.; Ricaurte, G.A. Sero-tonin neurotoxicity after (+/-)3,4-methylenedioxy-ethamphetamine(MDMA; Ecstasy): a controlled study in humans. Neuropsycho-pharmacology, 1994, 10(2), 129-138
42. Brody, S.; Krause, C.; Veit, R.; Rau, H. Cardiovascular autonomicdysregulation in users of MDMA (Ecstasy). Psychopharma-cology, 1998, 136(4), 390-393
43. Solowij, N.; Hall, W.; Lee, N. Recreational MDMA use in Sydney:a profile of 'Ecstacy' users and their experiences with the drug. Br.J. Addict., 1992, 87(8), 1161-1172
44. Cerretani, D.; Riezzo, I.; Fiaschi, A.I.; Centini, F.; Giorgi, G.; D'Errico, S.; Fiore, C.; Karch, S.B.; Neri, M.; Pomara, C.; Turil-lazzi, E.; Fineschi, V. Cardiac oxidative stress determination andmyocardial morphology after a single ecstasy (MDMA) administra-tion in a rat model. In.t J. Legal Med., 2008, 122(6), 461-469.
45. Milroy, C.M.; Clark, J.C.; Forrest, A.R. Pathology of deaths asso-ciated with ecstasy and eve misuse. J. Clin. Pathol., 1996,49(2), 149-153
46. Irvine, R.; Toop, N.P.; Phillis, B.D.; Lewanowitsch, T. The acutecardiovascular effects of 3.4-methylenedioxymethamphetamine(MDMA) and p-methoxyamphetamine (PMA). Addict. Biol., 2001,6, 45-54
47. Henry, J.A.; Jeffreys, K.J.; Dawling, S. Toxicity and deaths from3,4-methylenedioxymethamphetamine (ecstasy). Lancet, 1992,340(8816), 384-387
48. Burgess, C.; O'Donohoe, A.; Gill, M. Agony and ecstasy: a reviewof MDMA effects and toxicity. Eur. Psychiatry, 2000, 15(5), 287-294
49. Kaye, S.; Darke, S.; Duflou, J. Methylenedioxymethamphetamine(MDMA)-related fatalities in Australia: demographics, circum-stances, toxicology and major organ pathology. Drug Alcohol De-pend, 2009, 104(3), 254-261
50. Duflou, J.; Mark, A. Aortic dissection after ingestion of ecstasy(MDMA). Am. J. Forensic Med. Pathol., 2000, 21(3), 261-263.
51. Greene, S.L.; Dargan, P.I.; O'Connor, N.; Jones, A.L.; Kerins, M.Multiple toxicity from 3,4-methylenedioxymethamphetamine (ec-stasy). Am. J. Emerg. Med., 2003, 21(2), 121-124
52. Pilgrim, J.L.; Gerostamoulos, D.; Drummer, O.H.; Bollmann, M.Involvement of amphetamines in sudden and unexpected death. J.Forensic Sci., 2009, 54(2), 478-485
53. Madhok, A.; Boxer, R.; Chowdhury, D. Atrial fibrillation in anadolescent--the agony of ecstasy. Pediatr. Emerg. Care, 2003,19(5), 348-349
54. Sadeghian, S.; Darvish, S.; Shahbazi, S.; Mahmoodian, M. Twoecstasy-induced myocardial infarctions during a three month periodin a young man. Arch. Iran Med., 2007, 10(3), 409-412
55. Qasim, A.; Townend, J.; Davies, M.K. Ecstasy induced acute myo-cardial infarction. Heart, 2001, 85(6), E10
56. Lai, T.I.; Hwang, J.J.; Fang, C.C.; Chen, W.J. Methylene 3, 4 di-oxymethamphetamine-induced acute myocardial infarction. Ann.Emerg. Med., 2003, 42(6), 759-762
57. Wijetunga, M.; Seto, T.; Lindsay, J.; Schatz, I. Crystal metham-phetamine-associated cardiomyopathy: tip of the iceberg? J. Toxi-col. Clin. Toxicol., 2003, 41(7), 981-986
58. Patel, M.M.; Belson, M.G.; Wright, D.; Lu, H.; Heninger, M.; Miller, M.A. Methylenedioxymethamphetamine (ecstasy)-relatedmyocardial hypertrophy: an autopsy study. Resuscitation, 2005,66(2), 197-202
59. Yeo, K.K.; Wijetunga, M.; Ito, H.; Efird, J.T.; Tay, K.; Seto, T.B.; Alimineti, K.; Kimata, C.; Schatz, I.J. The association of metham-phetamine use and cardiomyopathy in young patients. Am. J. Med.,2007, 120(2), 165-171
60. Mizia-Stec, K.; Gasior, Z.; Wojnicz, R.; Haberka, M.; Mielczarek, M.; Wierzbicki, A.; Pstras, K.; Hartleb, M. Severe dilated cardio-myopathy as a consequence of Ecstasy intake. Cardiovasc. Pathol.,2008, 17(4), 250-253
61. Droogmans, S.; Cosyns, B.; D'Haenen, H.; Creeten, E.; Weytjens, C.; Franken, P.R.; Scott, B.; Schoors, D.; Kemdem, A.; Close, L.; Vandenbossche, J.L.; Bechet, S.; Van Camp, G. Possible associa-tion between 3,4-methylenedioxymethamphetamine abuse andvalvular heart disease. Am. J. Cardiol., 2007, 100(9), 1442-1445.
62. Setola, V.; Hufeisen, S.J.; Grande-Allen, K.J.; Vesely, I.; Glennon, R.A.; Blough, B.; Rothman, R.B.; Roth, B.L. 3,4-methyl-enedioxymethamphetamine (MDMA, Ecstasy) induces fenflu-ramine-like proliferative actions on human cardiac valvular intersti-tial cells in vitro. Mol. Pharmacol., 2003, 63(6), 1223-1229.
63. Shenouda, S.K.; Lord, K.C.; McIlwain, E.; Lucchesi, P.A.; Varner, K.J. Ecstasy produces left ventricular dysfunction and oxidativestress in rats. Cardiovasc. Res., 2008, 79(4), 662-670
64. Carvalho, M.; Remiao, F.; Milhazes, N.; Borges, F.; Fernandes, E.; Monteiro Mdo, C.; Goncalves, M.J.; Seabra, V.; Amado, F.; Car-valho, F.; Bastos, M.L. Metabolism is required for the expressionof ecstasy-induced cardiotoxicity in vitro. Chem. Res. Toxicol.,2004, 17(5), 623-632
65. Hiramatsu, M.; Kumagai, Y.; Unger, S.E.; Cho, A.K. Metabolismof methylenedioxymethamphetamine: formation of dihy-droxymethamphetamine and a quinone identified as its glutathioneadduct. J. Pharmacol. Exp. Ther., 1990, 254(2), 521-527.
66. Miller, R.T.; Lau, S.S.; Monks, T.J. 2,5-Bis-(glutathion-S-yl)-alpha-methyldopamine, a putative metabolite of (+/-)-3,4-methylenedioxyamphetamine, decreases brain serotonin concentra-tions. Eur. J. Pharmacol., 1997, 323(2-3), 173-180
67. Costa, V.M.; Silva, R.; Ferreira, L.M.; Branco, P.S.; Carvalho, F.; Bastos, M.L.; Carvalho, R.A.; Carvalho, M.; Remiao, F. Oxidationprocess of adrenaline in freshly isolated rat cardiomyocytes: forma-tion of adrenochrome, quinoproteins, and GSH adduct. Chem. Res.Toxicol., 2007, 20(8), 1183-1191
68. Costa, V.M.; Silva, R.; Ferreira, R.; Amado, F.; Carvalho, F.; deLourdes, B.M.; Carvalho, R.A.; Carvalho, M.; Remiao, F. Adrena-line in pro-oxidant conditions elicits intracellular survival pathwaysin isolated rat cardiomyocytes. Toxicology, 2009, 257(1-2), 70-79.
69. Jiang, J.P.; Downing, S.E. Catecholamine cardiomyopathy: reviewand analysis of pathogenetic mechanisms. Yale J. Biol. Med., 1990,63(6), 581-591
70. Bianchi, P.; Pimentel, D.R.; Murphy, M.P.; Colucci, W.S.; Parini, A. A new hypertrophic mechanism of serotonin in cardiac myo-cytes: receptor-independent ROS generation. FASEB J., 2005,19(6), 641-643.